Novel treatments for men with lower urinary tract symptoms suggestive of benign prostate hyperplasia
Journal
Journal of the Formosan Medical Association
Journal Volume
108
Journal Issue
5
Pages
349-352
Date Issued
2009
Author(s)
Chung S.-D.
SDGs
Other Subjects
5 [[(3 phenoxybenzyl)(1,2,3,4 tetrahydro 1 naphthyl)amino]carbonyl]trimellitic acid; alpha adrenergic receptor blocking agent; beta 3 adrenergic receptor stimulating agent; botulinum toxin A; capsaicin; cholinergic receptor blocking agent; endothelin 1; endothelin A receptor; endothelin B receptor; endothelin receptor antagonist; muscarinic receptor blocking agent; noradrenalin; phosphodiesterase V inhibitor; placebo; prostate specific antigen; purinergic P2X3 receptor; purinergic receptor blocking agent; resiniferatoxin; tamsulosin; tolterodine; vanilloid receptor 1; bladder capacity; bladder disease; chronic inflammation; clinical trial; dose response; drug efficacy; drug safety; drug targeting; human; lower urinary tract symptom; micturition; monotherapy; neuropathic pain; nonhuman; overactive bladder; prostate hypertrophy; receptor upregulation; short survey; spinal cord injury; treatment outcome; urge incontinence; urinary urgency; urodynamics
Publisher
Elsevier B.V.
Type
short survey